Control | RA | Asthma | IPF/NSIP | RA-ILD | |
---|---|---|---|---|---|
n = 10 | n = 10 | n = 10 | n = 5/n = 4 | n = 10 | |
Age, years, median (P25-P75) | 56 (51–59) | 58 (49–66) | 50 (36–56) | 75 (66–78) | 70 (55–75) |
Female sex, n (%) | 4 (40) | 7 (70) | 3 (30) | 4 (44) | 6 (60) |
Current/former/never smokers (%)1 | NA | 20/10/70 | 10/20/70 | 0/78/22 | 20/70/10 |
Blood sample results | |||||
Hemoglobin, mmol/L, median (P25-P75) | 9.1 (8.8–9.5) | 7.8 (7.2–8.8) | 9.1 (8.7–9.7) | 8.5 (7.8–8.9) | 8.25 (8–8.5) |
CRP, mg/L, median (P25-P75) | NA | 5.4 (2.7–16) | 3.2 (1.8–4.7) | 2.3 (2–4.4) | 8 (1.9–11) |
Leucocytes, 109/L, median (P25-P75) | 5.3 (4.6–5.8) | 6.8 (5.9–9.6) | 8.5 (8.1–9.1) | 9.6 (8.2–11) | 11.5 (6.7–14.5) |
Monocytes, 109/L, median (P25-P75) | 0.5 (0.4–0.6) | 0.6 (0.5–0.7) | 0.6 (0.5–0.8) | 0.8 (0.6–1.1) | 0.8 (0.7–1.0) |
Radiological signs compatible with interstitial lung disease and/or lung fibrosis2 | |||||
Chest X-ray (n/N) | 0/0 | 1/7 | 0/6 | 9/9 | 6/10 |
High Resolution CT (n/N) | 0/0 | 0/0 | 0/7 | 9/9 | 10/10 |
Pulmonary Function Test | |||||
Lungfunction performed (n/N) | 0/0 | 10/10 | 10/10 3 | 9/9 | 10/10 4 |
FVC (% predicted), median (P25-P75) | NA | 108 (103–16) | 84 (70–99) | 78 (66–90) | NA |
TLC (% predicted), median (P25-P75) | NA | 99 (94–103) | NA | 83 (64–93) | NA |
FEV1 (% predicted), median (P25-P75) | NA | 103 (92–112) | 71 (61–81) | 78 (72–85) | 70 (39–86) |
DLCOc (% predicted),median (P25-P75) | NA | 79 (67–89) 5 | NA | 36 (31–37) | 58 (46–73) |
Asthma patients | |||||
GINA score (Average) 6 | 5 | ||||
ACT score, median (P25-P75) | 18.5 (16–20) | ||||
RA patients | |||||
Disease Duration (Years), median (P25-P75) | 5.4 (2.4–17) | 11.8 (1.4–33) | |||
DAS28CRP, median (P25-P75) | 2.75 (1.9–3.8) | 3.4 (3–4.2) | |||
Anti-CCP positive (%)/RF positive (%) | 80/80 | 90/90 | |||
Erosive disease | 60% | 90% | |||
No treatment (%)/DMARDs (%)/Biological treatment (%) | 10/70/50 | 0/80/50 |